Skip to main content

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

CyTOF-ready, Immunocytochemistry, Intracellular Staining by Flow Cytometry

Cited:

Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2A Clone # 313203

Product Specifications

Immunogen

E. coli-derived recombinant human TRADD
Met1-Ala312
Accession # Q15628

Specificity

Detects human TRADD in direct ELISAs and Western blots. In Western blots, no cross-reactivity with  recombinant human (rh) BAFF R, rhTNF R1, rhHVEM, rhLT beta R, rhCD30, rhGITR, rh4-1BB, rhDR3, rhDR6, rhRANK, rhRELT, rhTAJ, rhEDAR, rhFas, recombinant mouse (rm) DC‑TRAIL R1, rmDC-TRAIL R2, rhTRAIL R3, rhTRAIL R4, rhNGF R, rhCD27, rhTNF RII, rhTWEAK R, rhTRAIL R2, or rhCD40 is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2A

Scientific Data Images for Human TRADD Antibody

TRADD antibody in MCF-7 Human Cell Line by Immunocytochemistry (ICC).

TRADD in MCF‑7 Human Cell Line.

TRADD was detected in immersion fixed MCF-7 human breast cancer cell line using Mouse Anti-Human TRADD Monoclonal Antibody (Catalog # MAB2658) at 3 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Applications for Human TRADD Antibody

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Immunocytochemistry

3-25 µg/mL
Sample: Immersion fixed MCF-7 human breast cancer cell line

Intracellular Staining by Flow Cytometry

0.25 µg/106 cells
Sample: Human peripheral blood lymphocytes fixed with paraformaldehyde and permeabilized with saponin

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRADD

TRADD (TNF R1A-associated death domain protein) is a 34 kDa protein that is expressed nearly ubiquitously. TRADD functions as an adaptor protein associating with the cytoplasmic domain of TNF receptor 1 or to another adaptor, FADD (Fas-interacting DD) to form the DISC (death inducing signaling complex). Human TRADD is an alpha-helical, Greek key, death domain-containing protein that is 77% identical to both mouse and rat TRADD.

Long Name

TNFRSF1A-associated via Death Domain

Alternate Names

MGC11078, TNFRSF1A-associated via death domainTNFR1-associated DEATH domain protein, tumor necrosis factor receptor type 1 associated death domain protein, tumor necrosis factor receptor type 1-associated DEATH domain protein, tumor necrosis factor receptor-1-associated protein

Entrez Gene IDs

8717 (Human)

Gene Symbol

TRADD

UniProt

Additional TRADD Products

Product Documents for Human TRADD Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human TRADD Antibody

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...